The Association of G9a Protein and the Outcome of Patients With Cervical Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01505751

Enrollment

Registered

2012-01-09

Start date

2012-02-29

Completion date

2015-02-28

Last updated

2016-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer

Keywords

Outcome of cervical cancer

Brief summary

G9a protein was approved to be highly associated with recurrence of breast cancer, gastric cancer, hepatocellular cancer, prostate cancer and lung cancer. Therefore, the aim of this study was to clarify the association and G9a protein and cervical cancer by analyzing the immunohistochemical staining of G9a protein to the histopathologic specimen of cervical cancer and clinical data.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 99 Years

Healthy volunteers

Inclusion criteria

* cases with cervical cancer

Design outcomes

Primary

Measure	Time frame
determine whether G9a protein is a risk factor of overall survival of patients with cervical cancer	From the date of primary treatment until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 100 months

Secondary

Measure	Time frame
determine whether G9a protein is a risk factor of progression-free survival of patients with cervical cancer	From the date of primary treatment until the date of first documented progression or last follow-up, whichever came first, assessed up to 100 months

Countries

Taiwan

Outcome results